Keyword Search
 
2018 | 2017 | 2016 | 2015
Motif Bio to Present Iclaprim Data at ECCMID 2018
February 21, 2018
Phase 3 trial results for REVIVE-2 in patients with ABSSSI Potential cost savings opportunities with iclaprim versus vancomycin Iclaprim in vitro susceptibility data NEW YORK, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that three iclaprim abstracts have been accepted for presentation at the upcoming 28th European Congress of Clinical Microbiology and Inf... Read More
Appointment of Jonathan E. Gold as Interim Chief Financial Officer
February 2, 2018
NEW YORK, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Dickey IV has informed the Company of his intention to resign from his role as Chief Financial Officer (CFO).  A search process for a new CFO has commenced and Jonathan E. Gold, currently a Non-executive Director of the Company, has agreed to serve as interim CFO.  ... Read More
Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group
January 29, 2018
WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Sp... Read More
Motif Bio Announces Filing of U.S. Shelf Registration
January 19, 2018
NEW YORK, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM/NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has filed a “universal” shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (the “SEC”). The filing of a shelf registration statement, a common practice by NASDAQ-listed companies, is intended to provide the Company with more timely and efficient access to the... Read More
Motif Bio Receives Award from Cystic Fibrosis Foundation
January 16, 2018
NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has received an award from the Cystic Fibrosis Foundation to fund important in vitro testing that will help to advance the development of iclaprim for the treatment of lung infections in patients with cystic fibrosis (CF). This is the first award that the Company has received from the Cysti... Read More
Motif Bio to participate in panel discussion at upcoming Cantor Antibiotics Summit
January 5, 2018
NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will participate in the following event: Cantor Antibiotics Summit January 17, 2018 Omni Berkshire Hotel New York, NY USA Graham Lumsden, Chief Executive Officer, will participate in a panel discussion, “Catalysts to Look for in 2018.” The Cantor Antibiotics Summit will bring togethe... Read More